Unknown

Dataset Information

0

Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.

ABSTRACT: Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matched samples before and after taxane/platinum-based neoadjuvant chemotherapy. All used markers of stemness (ALDH1, CD24, CD117, CD133) isolated low frequencies of malignant cells. ALDH1 was the most valuable marker for tracking stemness in vivo. The enrichment of ALDH1 expression after treatment was associated with a poor response to chemotherapy, with platinum resistance and independently prognosticated unfavorable outcome. Our results suggest that increased ALDH1 expression after treatment identifies patients with aggressive tumor phenotypes.

SUBMITTER: Ayub TH 

PROVIDER: S-EPMC4599280 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.

Ayub Tiyasha H TH   Keyver-Paik Mignon-Denise MD   Debald Manuel M   Rostamzadeh Babak B   Thiesler Thore T   Schröder Lars L   Barchet Winfried W   Abramian Alina A   Kaiser Christina C   Kristiansen Glen G   Kuhn Walther W   Kübler Kirsten K  

Oncotarget 20150601 18

Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matched samples before and after taxane/platinum-based neoadjuvant chemotherapy. All used markers of stemness (ALDH1, CD24, CD117, CD133) isolated low frequencies of malignant cells. ALDH1 was the most va  ...[more]

Similar Datasets

Unknown CIAPIN1 nuclear accumulation predicts poor clinical outcome in epithelial ovarian cancer.
| S-EPMC3502349 | biostudies-literature
Unknown Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer.
| S-EPMC5620008 | biostudies-literature
Unknown ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome.
| S-EPMC9019266 | biostudies-literature
Transcriptomics TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy
2021-12-10 | GSE190275 | GEO
Transcriptomics GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
2012-03-20 | E-GEOD-32646 | biostudies-arrayexpress
Transcriptomics COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
2014-01-01 | GSE44104 | GEO
Transcriptomics COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
2014-01-01 | E-GEOD-44104 | biostudies-arrayexpress
Transcriptomics GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
2012-03-20 | GSE32646 | GEO
Unknown Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
| S-EPMC8962250 | biostudies-literature
Unknown WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
| S-EPMC6929979 | biostudies-literature